Mortality data from omission of early thromboprophylaxis in critically ill patients highlights the importance of an individualised diagnosis-related approach

Table 2 Association between early thromboprophylaxis and mortality by pre-existing medical conditions

Pre-existing medical conditions	Odds ratios (95% CI)	P-value
Chronic respiratory disease (n = 106,833)
VTE prophylaxis
Yes	Ref
No	1.38 (1.27–1.50)	< 0.001
Contraindicated	1.10 (0.99–1.23)	0.069
Not indicated	1.31 (1.15–1.51)	< 0.001
Chronic cardiovascular disease (n = 131,038)
VTE prophylaxis
Yes	Ref
No	1.46 (1.34–1.57)	< 0.001
Contraindicated	1.28 (1.18–1.40)	< 0.001
Not indicated	1.24 (1.09–1.41)	0.001
Chronic renal failure (n = 48,970)
VTE prophylaxis
Yes	Ref
No	1.34 (1.20–1.49)	< 0.001
Contraindicated	1.32 (1.17–1.49)	< 0.001
Not indicated	1.32 (1.10–1.57)	0.026
Chronic liver disease (n = 25,058)
VTE prophylaxis
Yes	Ref
No	1.27 (1.11–1.45)	< 0.001
Contraindicated	1.23 (1.11–1.37)	< 0.001
Not indicated	1.30 (1.03–1.63)	0.026
Metastatic cancer (n = 56,101)
VTE prophylaxis
Yes	Ref
No	1.37 (1.21–1.54)	< 0.001
Contraindicated	1.34 (1.17–1.54)	< 0.001
Not indicated	1.29 (1.03–1.63)	0.029

Adjusted for Australian and New Zealand Risk of Death (ANZROD). ANZROD is derived from patient and clinical characteristics, including the Acute Physiology and Chronic Health Evaluation (APACHE) III, ICU admission source, admission diagnoses, Acute Physiology score (APS), APACHE III chronic health score, treatment limitation, and ventilation status. VTE-Venous thromboembolism

ISSN: 1477-9560